Precision CRISPR: Drug Development and Gene Therapy Congress returns for the 3rd time, just in time to face the building excitement in getting CRISPR gene therapy into the clinic. Take a look at the conference program and engage with this community today: https://bit.ly/2zdRx77
Through a dynamic program of focused sessions, interactive discussions and networking opportunities, you will leave this meeting with a deep understanding of:
- the challenges in delivery and reducing off-target effects in ex vivo and in vivo gene therapies
- how the likes of GSK, Novartis, AstraZeneca and more, work towards improving the efficacy of functional screening and drug discovery
- the most recent gene editing techniques and Cas variants poised to make precise gene editing all that more precise
Preview Agenda Highlights:
• Discover how to detect in vitro and ex vivo cellular indel profiles and dynamics induced by different CRISPR/Cas9 delivery formats with insights from Eric Paul Bennett, University of Copenhagen
• Explore how Jacob Corn, ETH Zurich is forwarding gene repair in Human Hematopoietic Stem Cells and progressing towards translation of gene editing therapies for sickle cell disease
• Find out how Barry Rosen, VP, AstraZeneca is utilising precise genome engineering to empower drug discovery
To find out more, get your event program here: https://bit.ly/2zdRx77
